TITLE

CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR)−mediated apoptosis

AUTHOR(S)
Lee, Y Y; Moujalled, D; Doerflinger, M; Gangoda, L; Weston, R; Rahimi, A; de Alboran, I; Herold, M; Bouillet, P; Xu, Q; Gao, X; Du, X-J; Puthalakath, H
PUB. DATE
July 2013
SOURCE
Cell Death & Differentiation;Jul2013, Vol. 20 Issue 7, p941
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Catecholamines regulate the β-adrenoceptor/cyclic AMP-regulated protein kinase A (cAMP/PKA) pathway. Deregulation of this pathway can cause apoptotic cell death and is implicated in a range of human diseases, such as neuronal loss during aging, cardiomyopathy and septic shock. The molecular mechanism of this process is, however, only poorly understood. Here we demonstrate that the β-adrenoceptor/cAMP/PKA pathway triggers apoptosis through the transcriptional induction of the pro-apoptotic BH3-only Bcl-2 family member Bim in tissues such as the thymus and the heart. In these cell types, the catecholamine-mediated apoptosis is abrogated by loss of Bim. Induction of Bim is driven by the transcriptional co-activator CBP (CREB-binding protein) together with the proto-oncogene c-Myc. Association of CBP with c-Myc leads to altered histone acetylation and methylation pattern at the Bim promoter site. Our findings have implications for understanding pathophysiology associated with a deregulated neuroendocrine system and for developing novel therapeutic strategies for these diseases.
ACCESSION #
88057107

 

Related Articles

  • Srdce v septickém Å¡oku a beta blokáda -- paradox k zamyÅ¡lení? Matějovič, Martin // Anaesthesiology & Intensive Medicine / Anesteziologie a Intenziv;2013, Vol. 24 Issue 6, p403 

    Myocardial depression is a well-recognized consequence of septic shock. A growing body of evidence suggests that excessive catecholamine levels exert toxic effects on the heart, thereby contributing to the development of septic myocardial dysfunction. Although seemingly counter-intuitive,...

  • Beta-blocker use did not improve survival in patients with melanoma.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p46 

    The article discusses a study published by researcher Livingstone and colleagues in the 2013 issue of "European Journal of Cancer" which found that beta-blocker use did not improve overall survival (OS) among melanoma patients.

  • Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. A letter to the authors. Zante, Bjoern; Wirtz, Sebastian // Wiener Klinische Wochenschrift;Jan2013, Vol. 125 Issue 1/2, p54 

    A letter to the editor is presented in response to the article "Concomitant Use of Beta-1 Adrenergic Blocker and Norepinephrine in Patients With Septic Shock," by M. Balik in a 2012 issue.

  • Effect of carvedilol on cardiomyocyte apoptosis in a rat model of myocardial infarction: A role for toll-like receptor 4. Jianhua Zhang; Qingwei Liu; Yan Xu; Ying Huang; Changhao Wu // Indian Journal of Pharmacology;Sep-Oct2013, Vol. 45 Issue 5, p458 

    Objectives: Toll-like receptor 4 (TLR4) is crucial in cardiomyocyte apoptosis induced by myocardial infarction (MI) and carvedilol has been reported to have anti-apoptotic effects. We hypothesized that the effects of this agent are in part mediated through TLR4 signaling pathways. Materials and...

  • Do beta blockers improve the lives of heart patients?  // Cat Watch;Jan2013, Vol. 17 Issue 1, p1 

    The article focuses on a research performed by North Carolina State University to study if early medical therapy of beta blockers improves the quality of life in cats, suffering with hypertrophic cardiomypathy patients.

  • Beta blocker use not associated with decreased risk of colorectal cancer.  // Australian Journal of Pharmacy;Nov2012, Vol. 93 Issue 1110, p98 

    The article discusses a study conducted by L. Jansen and colleagues on the long-term use of beta blockers which may lessen the risk of certain types of cancer such as colorectal cancer (CRC) due to the weakening of norepinephrine signalling.

  • Beta-blockers for heart failure: Why you should use them more. Ong, Hean T.; Kow, Fei P. // Journal of Family Practice;Aug2011, Vol. 60 Issue 8, p472 

    The article focuses on the use of beta-blockers such as bisoprolol, carvedilol and metoprolol succinate to reduce morbidity and mortality in systolic heart failure patients. It states that the Carvedilol or Metoprolol European Trial (COMET) found the carvedilol is better at extending survival...

  • β-blockers may cut risk of death in COPD patients.  // Pulse;6/2/2010, Vol. 70 Issue 19, p11 

    The article reports on the study conducted by Professor Frans Rutten on the efficacy of β-blockers to reduce patient death in chronic obstructive pulmonary disease (COPD) of patients in Rotterdam, Netherlands.

  • Post-MI beta blocker doses too low. Gebhart, Fred // Drug Topics;Dec2010, Vol. 154 Issue 12, p29 

    The article presents a study on the use of pacemaker-facilitated beta blocker therapy after myocardial infarction (MI) of patients contraindicated to beta blockers, the PACE-MI trial. The study which involved MI patients from various medical centers who had beta blocker doses at discharge is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics